Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Eisai to Apply for Eribulin in Japan, the US and Europe in March
January 25, 2010
- 61% of Drug Companies Welcome New Pricing System: Questionnaire
January 25, 2010
- MK-8669 Enters PII in Japan: Banyu
January 25, 2010
- Panel of Experts on Unapproved Drugs/Indications to Be Inaugurated
January 25, 2010
- MBL, Osaka Univ. Isolate Fully-Human Flu Virus MAB
January 25, 2010
- Avastin + Chemotherapy Improves PFS in Advanced Breast Cancer Patients
January 18, 2010
- Meiji Seika Aims at Becoming “Specialty & Generic”Pharma
January 18, 2010
- Tykerb + Herceptin Prolongs OS in Advanced Breast Cancer Patients
January 18, 2010
- Improvement of Infrastructures Essential to Promote Development of Biomarkers
January 18, 2010
- Mochida, MTPC to Comarket Escitalopram
January 18, 2010
- Rivaroxaban Reduces Recurrence of Symptomatic VTE: Bayer
January 18, 2010
- Kitasato Ins., Keio Univ. Chosen as Global Clinical Research Centers
January 18, 2010
- Daiichi Sankyo Acquires PharmaForce through Luitpold
January 18, 2010
- KRAS Gene Test Conducted in Only 12% of Patients
January 18, 2010
- Proposed GLs for Oral Hypoglycemic Agents Require Long-Term Studies on All Two-Drug Combinations
January 18, 2010
- Novartis Obtains Diovan's Successor by Acquiring Corthera
January 18, 2010
- Prof. Yamanaka Shows Great Hope for CP-690550 as 4th-Generation Immunosuppressant
January 18, 2010
- AnGes Terminates Cross Licensing Agreement for NF-кB
January 18, 2010
- Fall in the Number of OB/GYN Doctors Halted: Korosho
January 18, 2010
- 1st Product Using Elan's DDS Technology Approved in Japan
January 18, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…